Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine vs Sufentanil for PCIA in CPA Surgery
NCT07479446Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of oliceridine in postoperative nausea and vomiting (PONV) and postoperative pain (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Incidence of Postoperative Nausea. Started Mar 2026; status: recruiting.
02
Drugs
oliceridine
03
Conditions
postoperative nausea and vomiting (PONV)postoperative pain
Beyond the preview
Go deeper on NCT07479446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479446.